Novartis Ag (NVS) Long-Term Deferred Tax (2009 - 2026)

Novartis Ag (NVS) has 12 years of Long-Term Deferred Tax data on file, last reported at $600.0 million in Q1 2026.

• Quarterly Long-Term Deferred Tax changed N/A year-over-year to $600.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $600.0 million (changed N/A YoY) and the FY2025 annual result came in at $5.4 billion, up 1069.46% from the prior year.
• Long-Term Deferred Tax declined to $600.0 million in Q1 2026 per NVS's latest filing, from $5.4 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $5.4 billion in Q4 2025, with the low at $34.0 million in Q4 2023.
• Average Long-Term Deferred Tax over 5 years is $1.9 billion, with a median of $600.0 million recorded in 2026.
• The widest YoY moves for Long-Term Deferred Tax: up 7528.3% in 2023, down 99.09% in 2023.
• Novartis Ag's Long-Term Deferred Tax stood at $3.7 billion in 2022, then slumped by 99.09% to $34.0 million in 2023, then surged by 1267.65% to $465.0 million in 2024, then soared by 1069.46% to $5.4 billion in 2025, then slumped by 88.97% to $600.0 million in 2026.
• Business Quant data shows NVS's Long-Term Deferred Tax at $600.0 million in Q1 2026, $5.4 billion in Q4 2025, and $5.2 billion in Q2 2025.